Robert Osborne, PhD, Senior Vice President of Research & Development provides a high-level overview of biomodal’s bioRXiv preprint, 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) are synergistic biomarkers for early detection of colorectal cancer. During this interview, he will discuss the roles of 5mC and 5hmC as biomarkers for early-stage colorectal cancer (CRC) detection in cell-free DNA (cfDNA).
What can you expect to learn:
- The expanding potential of liquid biopsy for early cancer detection by distinguishing between 5mC and 5hmC to improve the sensitivity of liquid biopsy tests.
- Methylation states of enhancers in CRC cfDNA samples provide evidence that 5mC and 5hmC track cancer stage with greater precision.
- Together, the 5mC and 5hmC model shows an 85% sensitivity (at 95% specificity) for early-stage cancer detection.
- Early-stage detection, CRC 5hmC is shown to provide complementary information to that of 5mC.
This groundbreaking data is a paradigm shift for liquid biopsy and cancer research.
